The U.S. Food and Drug Administration has approved a four-week dosing schedule for Bristol-Myers Squibb's cancer drug, Opdivo.
A two-week dosing had already been approved previously and now BMS have announced that the drug is also approved for 30-minute infusions, down from the previous 60-minute infusions.
While the PD-1 inhibitor Opdivo has rivals from Merck and Roche, it is now the only inhibitor to offer four-week dosing.
Read the Reuters report